Introduction to Biostatistics
Transcript of Introduction to Biostatistics
![Page 1: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/1.jpg)
Acute Medical Acute Medical Stroke TherapyStroke Therapy
Gregory W. Albers, MDGregory W. Albers, MD
Professor of Neurology and Professor of Neurology and Neurological SciencesNeurological Sciences
Director, Stanford Stroke CenterDirector, Stanford Stroke Center
![Page 2: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/2.jpg)
Acute Medical Acute Medical Treatment of StrokeTreatment of Stroke
• Restore Blood FlowRestore Blood Flow– ThrombolyticsThrombolytics– Mechanical devicesMechanical devices
Stroke progression Stroke progression or recurrent or recurrent thromboembolismthromboembolism – AnticoagulantsAnticoagulants– Antiplatelet agentsAntiplatelet agents
![Page 3: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/3.jpg)
How would you treat this patient?
72 yo male with aphasia and right hemiparesis
NIH =18
• If he presents at 2 hours?• If he presents at 5 hours?
![Page 4: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/4.jpg)
NINDS tPA Stroke TrialNINDS tPA Stroke Trial
0
10
20
30
0
10
20
30
tPA tPAPlacebo Placebo
31
20 9
8
20
1
NIHSS Excellent Recovery (%)
Total Death Rate (%)
Hemorrhagep < .05
New England Journal, 1995
![Page 5: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/5.jpg)
Large Randomized Trials of IV tPA Large Randomized Trials of IV tPA for Treatment of Acute Strokefor Treatment of Acute Stroke
Study N Dose Time Window Study N Dose Time Window
ECASS I ECASS I 650 650 1.1 1.1 0 – 6 0 – 6
NINDS NINDS 624624 0.9 0.9 0 – 3 0 – 3
ECASS II ECASS II 800800 0.9 0.9 0 – 6 0 – 6
ATLANTIS A 142ATLANTIS A 142 0.9 0.9 0 – 6 0 – 6
ATLANTIS BATLANTIS B 619619 0.9 0.9 3 – 5 3 – 5
![Page 6: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/6.jpg)
Pooled AnalysisPooled Analysis
Odds Ratios for Favorable OutcomeOdds Ratios for Favorable Outcome
TimeTime Odds Ratio 95% (CI) Interval Odds Ratio 95% (CI) Interval
0-900-90 2.8 2.8 1.8 - 4.51.8 - 4.5
91-18091-180 1.5 1.5 1.1 - 2.11.1 - 2.1
181-270181-270 1.4 1.4 1.1 - 1.91.1 - 1.9
271-360271-360 1.2 1.2 0.9 - 1.50.9 - 1.5
![Page 7: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/7.jpg)
Stroke CodeStroke Code
• Who is eligible for tPA?Who is eligible for tPA?
• What needs to be checked What needs to be checked before starting the tPA infusion?before starting the tPA infusion?
• Common errors to avoidCommon errors to avoid
![Page 8: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/8.jpg)
Early Infarct Signs: Guidelines for Early Infarct Signs: Guidelines for Patients with Clearly Established Stroke Patients with Clearly Established Stroke
Onset and Treatment Within 3 hrsOnset and Treatment Within 3 hrs
• tPA eligibletPA eligible
• not predictive of not predictive of an unfavorable an unfavorable response to tPAresponse to tPA
• insufficient datainsufficient data
• withholding tPA withholding tPA recommended recommended (Level C data )(Level C data )
Subtle early infarct signs (regardless of size)
Extensive andclearly identifiable hypodensity (>1/3 MCA territory)
![Page 9: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/9.jpg)
Stroke CodeStroke Code
• Who is eligible for tPA?Who is eligible for tPA?
• What needs to be checked What needs to be checked before starting the tPA infusion?before starting the tPA infusion?
• Common errors to avoidCommon errors to avoid
![Page 10: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/10.jpg)
Stroke CodeStroke Code
Nursing – if patient is found to have symptoms of a Nursing – if patient is found to have symptoms of a strokestroke• Confirm symptoms with resource RN immediatelyConfirm symptoms with resource RN immediately• Resource RN calls primary teamResource RN calls primary team• Pt’s RN calls Page Operator to initiate Stroke Pt’s RN calls Page Operator to initiate Stroke
CodeCode• Then gather:Then gather:
Brief historyBrief history Reason for thinking patient had a strokeReason for thinking patient had a stroke Last time patient seen normalLast time patient seen normal Current vital signsCurrent vital signs
![Page 11: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/11.jpg)
Stroke CodeStroke Code
Neurology Resident – will be paged by page Neurology Resident – will be paged by page operator on operator on stroke code pagerstroke code pager with text with text message : message : “Stroke Code: Room xxxx”“Stroke Code: Room xxxx”
• Must respond to bedside within Must respond to bedside within 5 minutes5 minutes• If patient is thought to be having a stroke If patient is thought to be having a stroke
then:then:– Activate Brain Attack Team (BAT) Code Activate Brain Attack Team (BAT) Code
ImmediatelyImmediately
![Page 12: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/12.jpg)
Stroke CodeStroke Code
Brain Attack Team consists of:Brain Attack Team consists of:– Critical Care Crisis RNCritical Care Crisis RN– CT TechCT Tech– TransportTransport– Nursing SupervisorNursing Supervisor– Stroke Fellow/Attending Stroke Fellow/Attending (specify)(specify)
![Page 13: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/13.jpg)
Stroke CodeStroke Code
Neurology ResidentNeurology Resident
• Carries Carries “stroke code” “stroke code” pagerpager• Responds to Stroke Code immediatelyResponds to Stroke Code immediately• Determines if Brain Attack Team (BAT) Determines if Brain Attack Team (BAT)
needs to be activatedneeds to be activated• If yes:If yes:
• Orders labsOrders labs• Orders CT or MRIOrders CT or MRI• EKG if neededEKG if needed• NIHSSNIHSS
![Page 14: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/14.jpg)
Stroke CodeStroke Code
Stroke Fellow/AttendingStroke Fellow/Attending• CT or MRI scan evaluationCT or MRI scan evaluation• Determines if tPA criteria is met or if Determines if tPA criteria is met or if
Neurosurgery/Neuroradiology needs to be Neurosurgery/Neuroradiology needs to be consultedconsulted
• Confirms NIHSSConfirms NIHSS• Writes tPA orders if appropriateWrites tPA orders if appropriate• Family communication and consentFamily communication and consent
![Page 15: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/15.jpg)
How Often Should Full Dose Anticoagulation Be Used for Treatment of Acute Stroke?
A. Often used for multiple stroke subtypesA. Often used for multiple stroke subtypes B. Rarely used, except for cardioembolicB. Rarely used, except for cardioembolic C. Rarely used for any stroke subtypeC. Rarely used for any stroke subtype
![Page 16: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/16.jpg)
Guidelines for Guidelines for Anticoagulant TherapyAnticoagulant Therapy
Urgent administration of anticoagulants Urgent administration of anticoagulants
has not yet been associated with has not yet been associated with lessening the risk of early recurrent lessening the risk of early recurrent stroke or improving outcomes. Because stroke or improving outcomes. Because it can increase the risk of brain it can increase the risk of brain hemorrhage, routine use cannot be hemorrhage, routine use cannot be recommendedrecommended..
American Heart Association, 2003
![Page 17: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/17.jpg)
Guidelines for Guidelines for Anticoagulant TherapyAnticoagulant Therapy
Anticoagulants are Anticoagulants are notnot recommended for recommended for
any subgroup of patients with acute stroke any subgroup of patients with acute stroke based on any presumed mechanism or based on any presumed mechanism or location (e.g., cardioembolic, large vessel location (e.g., cardioembolic, large vessel atherosclerotic, vertebrobasilar, or atherosclerotic, vertebrobasilar, or “progressing” stroke) because data are “progressing” stroke) because data are insufficientinsufficient..
American Academy of Neurology / AHA, 2003
![Page 18: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/18.jpg)
Anticoagulation for Anticoagulation for Acute Stroke Acute Stroke
Heparin in Acute Stable Stroke (n=212)Heparin in Acute Stable Stroke (n=212)
Stroke progression Stroke progression ImprovementImprovement
PlaceboPlacebo 20%20% 24% 24%
HeparinHeparin 17%17% 27% 27%
Duke, Ann Int Med 1986
![Page 19: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/19.jpg)
International Stroke TrialInternational Stroke TrialRecurrent Stroke Within 14 DaysRecurrent Stroke Within 14 Days
(N = 19,435)(N = 19,435)
![Page 20: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/20.jpg)
Nadroparin (Fraxiparin) Nadroparin (Fraxiparin) Stroke StudiesStroke Studies
![Page 21: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/21.jpg)
TOAST StudyTOAST Study
![Page 22: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/22.jpg)
TOAST StudyTOAST Study
![Page 23: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/23.jpg)
Treatment of Acute
Cardioembolic Stroke
![Page 24: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/24.jpg)
*no benefit in cardioembolism subgroup
Recent Trial Results
TrialTrial Recurrent Stroke Recurrent Stroke (%)(%)
IST (AF subgroup) Heparin 2.8(N = 3169) No heparin 4.9
TOAST (cardioembolism) Danaparoid 0(N = 266) Placebo 1.6
HAEST (all with AF) Dalteparin 8.5(N = 449) Aspirin 7.5
TAIST* HD Tinzaparin 3.3(N = 1484) LD Tinzaparin 4.7
Aspirin 3.1
![Page 25: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/25.jpg)
Risk of Early Stroke Recurrence
Multiple recent emboli
Mechanical heart valve
Atrial fibrillation + high risk features
Established intra-cardiac thrombus
Treatment of AcuteCardioembolic Stroke
![Page 26: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/26.jpg)
Risk of Hemorrhagic Complications
Anticoagulation increases the risk of extracranial hemorrhage by about 2%
Spontaneous hemorrhagic transformation is common and usually asymptomatic
Anticoagulation increases the risk of symptomatic ICH by about 2%
Treatment of AcuteCardioembolic Stroke
![Page 27: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/27.jpg)
Risk Factors for Symptomatic ICH
Infarct size
Timing of reperfusion (12 - 48 hours)
Excesssive anticoagulation / tPA
Heparin bolus?
Severe hypertension?
Treatment of AcuteCardioembolic Stroke
![Page 28: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/28.jpg)
Aspirin forAspirin forTreatment of Acute Stroke Treatment of Acute Stroke
• International Stroke Trial International Stroke Trial (IST, N = 19,435) (IST, N = 19,435)
• Chinese Acute Stroke Trial Chinese Acute Stroke Trial (CAST N = 21,106)(CAST N = 21,106)
![Page 29: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/29.jpg)
International Stroke TrialInternational Stroke TrialRecurrent Stroke Within 14 DaysRecurrent Stroke Within 14 Days
![Page 30: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/30.jpg)
International Stroke TrialInternational Stroke Trial
![Page 31: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/31.jpg)
Guidelines for Guidelines for Aspirin TherapyAspirin Therapy
• Early aspirin therapy (160-325 mg/day) is Early aspirin therapy (160-325 mg/day) is recommended recommended Grade 1AGrade 1A
• Delay aspirin for at least 24 hours after tPADelay aspirin for at least 24 hours after tPA
• Aspirin can be used safely in combination Aspirin can be used safely in combination with low doses of subcutaneous heparinwith low doses of subcutaneous heparin
Acute Ischemic Stroke
![Page 32: Introduction to Biostatistics](https://reader036.fdocuments.us/reader036/viewer/2022062513/556c4288d8b42a23608b476c/html5/thumbnails/32.jpg)
Guidelines for Guidelines for Acute Stroke TherapyAcute Stroke Therapy
• tPA is recommended for eligible patients within tPA is recommended for eligible patients within
3 hours of stroke onset 3 hours of stroke onset Grade 1AGrade 1A
• Aspirin is recommended for non-tPA eligible Aspirin is recommended for non-tPA eligible patients patients Grade 1AGrade 1A
• Use of full-dose anticoagulation with Use of full-dose anticoagulation with intravenous, subcutaneous, or low molecular intravenous, subcutaneous, or low molecular weight heparins or heparinoids should be weight heparins or heparinoids should be avoided avoided Grade 2BGrade 2B
ACCP, 2004